Compass Pathways: 3 Key Takeaways for Long-Term Investors

Compass Pathways announced it will complete its New Drug Application submission for COMP360 within two weeks, positioning its synthetic psilocybin candidate for treatment-resistant depression. The company benefits from an established network of 8,500+ interventional psychiatry clinics, with 90% of surveyed psychiatrists willing to prescribe COMP360. With $444 million in cash reserves, the company is well-funded through 2028 and the planned 2027 commercial launch.